Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

in vivo Imaging System

By Drug Discovery Trends Editor | September 30, 2008

CRi in vivo imaging systemCRi announced an imaging system for live mice that provides autofluorescence removal from images. The CRi Maestro EX In-Vivo Imaging System uses the firm’s patented FLEX technology, which allows broad- or narrow-bandwidth (±10-20 nm) imaging to permit greater throughput and increased multiplexing. Featuring spectral unmixing software tools and a configurable imaging area, this system can acquire multispectral images in seconds, image any fluorophore which emits beyond 500 nm, and is up to 300 times more sensitive than monochrome, according to the company.

Equipped with a light-tight chamber, Xenon-based illuminator, and liquid crystal tunable multispectral camera, the CRi Maestro EX In-Vivo Imaging System incorporates proprietary algorithms that yield images reflecting the true abundance of each marker isolated from others. This allows quantitating more markers accurately, resolving overlapping emission signals, including autofluorescence and allows longitudinal studies on one animal.

The CRi Maestro EX In-Vivo Imaging System is available with an optional heated stage, anesthesia kit, and an all-optical Dynamic Contrast Enhancement (DyCE) tool that generates anatomic organ maps.

CRi 


Filed Under: Drug Discovery

 

Related Articles Read More >

NIH is reorganizing clinical trial funding by trial type instead of disease
Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE